Myeloma

Myeloma
#CAR-T #Cell and gene therapy #Cell therapy #FDA #Myeloma #Poseida Therapeutics #Roche

‘Off-the-shelf’ CAR-T secures FDA advanced therapy designation

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Roche and Poseida Therapeutics’ P-BCMA-ALLO1. P-BCMA-ALLO1 is an investigational stem cell memory T cell (TSCM)-based allogeneic CAR-T cell therapy in Phase I/Ib clinical development for the treatment of patients with relapsed/refractory multiple myeloma. The… Read More

#News #Regulatory

CAR-T therapy
#CAR-T #Cell therapy #China #Legend Biotech #Myeloma #Oncology

Legend Biotech secures China cilta-cel approval for multiple myeloma

Legend Biotech (a subsidiary of GenScript Biotech) has received approval from the China National Medical Products Administration (NMPA) for cell therapy product, ciltacabtagene autoleucel (cilta-cel). The treatment is approved for use in adults with relapsed or refractory multiple myeloma (MM) who have undergone at least three prior lines of therapy,… Read More

#News #Regulatory

Johnson & Johnson head office
#Bispecific therapeutics #GlobalData #Johnson & Johnson #Myeloma #National Institute for Health and Care Excellence (NICE)

J&J will dominate bispecific T-cell engager market

Tecvayli (teclistamab) has been recommended for relapsed and refractory multiple myeloma (RRMM) in England and Wales, leading analysts to predict Johnson & Johnson (J&J) will dominate the bispecific T-cell engagers (BiTEs) market by 2030. The UK National Institute for Health and Care Excellence (NICE) recommended teclistamab… Read More

#News

Woman using mobile phone
#Charity #Clinical trials #Myeloma

New search tool to help myeloma patients find clinical trials

Myeloma Patients Europe (MPE) has launched a new online tool to facilitate the search of clinical trials in myeloma. The Myeloma and AL Amyloidosis European Clinical Trial Navigator is designed to help patients find clinical trials for myeloma, monoclonal gammopathy of undetermined significance (MGUS), smouldering multiple… Read More

#News

CAR-T therapy
#CAR-T #European Commission #Janssen #Myeloma #Oncology #Phase III trial

EC expands use of BCMA-targeted CAR-T therapy

The European Commission (EC) has approved a Type II variation for Carvykti (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM). It is approved in patients who have received at least one prior therapy, including an immunomodulatory agent (IMiD) and a proteasome inhibitor… Read More

#News #Regulatory

Multiple myeloma
#Blood cancer #Menarini #Myeloma #National Institute for Health and Care Excellence (NICE) #Oncology

Novel multiple myeloma drug recommended for UK NHS use

The UK’s National Institute for Health and Care Excellence (NICE) has published draft guidance recommending the use of Nexpovio (selinexor), in combination with bortezomib and dexamethasone, as a treatment for eligible multiple myeloma patients who have received one or two prior treatments. The recommendation follows recent NICE guidance recommending Nexpovio,… Read More

#News #Regulatory

FDA
#Adverse event #FDA #Myeloma #Oncology #Oncopeptides

FDA withdraws approval of Oncopeptides’ Pepaxto

The US Food and Drug Administration (FDA) has announced its final decision to withdraw approval of Pepaxto (melphalan flufenamide), despite an appeal by manufacturer Oncopeptides. The drug was originally approved for use in combination with dexamethasone to treat some patients with multiple myeloma. Approval was withdrawn as the confirmatory study… Read More

#News #Regulatory #Trending News

CAR-T therapy
#CAR-T #Cell therapy #CHMP #European Medicines Agency #Myeloma #Oncology

CAR-T therapy recommended for melanoma after first relapse

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a Type II variation for Carvykti (ciltacabtagene autoleucel; cilta-cel) for the earlier treatment of relapsed and refractory multiple myeloma (RRMM). The recommended indication for cilta-cel is for the treatment of… Read More

#News #Regulatory

Myeloma cells
#Blood cancer #CellCentric #Haematology #Myeloma #Oncology #Phase I trial

New class of drug shows promise in last line multiple myeloma

Data presented at the American Society for Hematology meeting (ASH) show a 70% response rate in last line multiple myeloma patients treated with CellCentric’s inobrodib in combination with pomalidomide (pom) and dexamethasone (dex). Inobrodib is the first in a new class of drug, which disrupts the… Read More

#Cancer Research #News

Multiple myeloma
#Bristol Myers Squibb #CAR-T #Cell therapy #Immunotherapy #Japan #Myeloma

First CAR-T therapy approved for earlier use in treatment of myeloma

Bristol-Myers Squibb has received manufacturing and marketing approval in Japan for Abecma (idecabtagene vicleucel) as a third-line therapy for relapsed or refractory multiple myeloma (RRMM). Abecma is a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy. It is now approved for RRMM patients who have received at… Read More

#News #Regulatory

Multiple myeloma
#Arcellx #CAR-T #Cell therapy #Clinical trial #Haematology #Myeloma #Oncology #Phase I trial

CART-ddBCMA trial shows durable response in myeloma patients

Arcellx has revealed encouraging interim data from its Phase I study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma. The company plans to present new data with a median follow-up of 26.5 months at the 65th American Society of Hematology (ASH) Annual Meeting and… Read More

#Cancer Research #News

Myeloma cells
#Cancer research #Janns #Janssen #Myeloma #National Institute for Health and Care Excellence (NICE) #Oncology

UK regulator gives green light to combination for multiple myeloma

The National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) in combination with lenalidomide and dexamethasone (DLd) for untreated multiple myeloma (MM) for routine use on the NHS in England and Wales. The therapy is now recommended within an NHS setting for the treatment of adults with… Read More

#News #Regulatory

European Commission
#Bispecific Antibodies #EU #European Commission #Janssen #Myeloma #Oncology

“Important new approach” to myeloma now available in the EU

The European Commission (EC) has granted conditional marketing authorisation (CMA) for Janssen’s Talvey (talquetamab) as monotherapy for relapsed and refractory multiple myeloma (RRMM). It is approved in adult patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have… Read More

#News #Regulatory

Multiple myeloma
#Accelerated assessment #Bispecific Antibodies #FDA #Immunotherapy #Myeloma #Pfizer #Phase II trial

FDA accelerates approval for multiple myeloma immunotherapy

The US Food and Drug Administration (FDA) has granted accelerated approval to Pfizer’s Elrexfio (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). The drug is approved in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory… Read More

#News #Regulatory

FDA
#Bispecific Antibodies #FDA #Janssen #Myeloma #Oncology

Janssen myeloma drug approved in US via a restricted programme

The FDA has granted accelerated approval to Janssen’s talquetamab-tgvs (Talvey) for adults with relapsed or refractory multiple myeloma. It has been approved in patients who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Talquetamab is a bispecific… Read More

#News #Regulatory

Multiple myeloma
#Bispecific Antibodies #Cancer research #CHMP #EMA #Janssen #Myeloma #Oncology

CHMP recommendation for bispecific antibody talquetamab

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorisation for Janssen’s Talvey (talquetamab). The drug has received a positive opinion for use as a monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who… Read More

#News #Regulatory